Calluna Pharma

Calluna Pharma is a clinical-stage biotech targeting the root causes of inflammation and fibrosis through a novel platform centered on Damage Associated Molecular Pattern (DAMP) proteins. Its lead asset, an anti-S100A4 antibody (CAL101), is in Phase 2 for IPF, with a broader pipeline targeting oxidized phospholipids (oxPLs) for other chronic inflammatory conditions. The company leverages over 30 years of foundational research from its co-founders and has established a key strategic alliance with Eli Lilly, positioning it to address significant unmet medical needs in large and growing markets.

Platform targeting upstream innate immune amplifiers, specifically Damage Associated Molecular Pattern (DAMP) proteins like S100A4 and oxidized phospholipids (oxPLs), to modulate a wide range of inflammatory and fibrotic signaling pathways.

Calluna competes in the crowded fibrosis and inflammation space, going against both approved anti-fibrotics (e.g., pirfenidone, nintedanib) and numerous biotechs targeting cytokines, growth factors, and immune cells. Its differentiation lies in its upstream, innate immune-focused approach targeting DAMPs, a novel mechanism that, if proven, could offer broader efficacy across multiple disease pathways.